pronton pump

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

S-Pantoprazole (sodium trihydrate), a variant of Pantoprazole, is pivotal in managing diseases associated with gastric acid secretion disorders, serving as a proton pump inhibitor [1].

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole-[D6] Sodium Salt (Standard) is a reference standard of Pantoprazole-[D6] Sodium Salt intended for quantitative analysis, quality control, and related biochemical research applications.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole-D6 is a deuterated compound of Pantoprazole. Pantoprazole (T6928) has a CAS number of 102625-70-7. Pantoprazole (T6928) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

(R)-(+)-Pantoprazole ((R)-(+)-BY1023) sodium is a proton pump inhibitor used in the study of esophageal erosion and ulcers.

Pantoprazole sulfide is a metabolite of the gastric H+/K+ ATPase pump inhibitor pantoprazole . Pantoprazole is metabolized by the cytochrome P450 (CYP) isomers CYP2C19 and CYP3A4 to form pantoprazole sulfide.

Pantoprazole-D8 is a deuterium-labeled version of Pantoprazole. Pantoprazole (T6928) (BY1023) is an orally active, potent proton pump inhibitor (PPI). As a substituted benzimidazole, Pantoprazole (T6928) effectively inhibits H+/K+-ATPase with an IC50 of 6.8 μM. It enhances pH stability and possesses antisecretory and anti-ulcer properties. When combined with Doxorubicin, Pantoprazole (T6928) significantly extends tumor growth delay.